Brian M. Paegel (rhymes with “bagel”) earned his undergraduate degree in chemistry from Duke University and his doctoral degree in chemistry from UC Berkeley working on miniaturized and integrated DNA sequencing technology development in collaboration with the Human Genome Project. He pursued postdoctoral studies in chemical biology and molecular evolution at Scripps Research. There, he studied the continuous evolution of catalytic RNAs, developing microfluidics for automation, reaction monitoring, and droplet compartmentalization. He was the recipient of both a NIH National Research Service Award (F32) and a Pathway to Independence Award (K99/R00). In 2008, Paegel was appointed to the Scripps chemistry faculty, starting his independent career at the new east coast campus of Scripps Research in Jupiter, Florida. He received the NIH Director’s New Innovator award and an NSF CAREER award in recognition of his contributions in reaction miniaturization for enzyme evolution, and Scripps granted him tenure in 2017 for his work in the field of DNA-encoded libraries and drug discovery technology development. In 2019, Paegel rejoined the University of California System where he is Professor in the Departments of Pharmaceutical Sciences, Chemistry, and Biomedical Engineering at Irvine. His laboratory aims to deliver advanced parallel synthesis and screening platforms to support cross-disciplinary translational research initiatives. Paegel is deploying these platforms to eliminate the canonical sense of what is “druggable” within the cellular milieu and to democratize the discovery of new medicines. To this end, he has co-founded four start-up companies in the biotechnology and drug discovery space.
Dr. Gandhi is co-founder and Chief Science Advisor of Translucence Biosystems. While a professor at UC Irvine, he focused his scientific career on developing technology to tap the brain’s latent capacity to rewire itself. His lab pioneered the application of inhibitory neuronal transplantation to correct developmental miswiring in mouse models of blindness. More recently, his group created new methods to visualize where neurological drugs have their effect using brain clearing technology and light sheet microscopy. For his efforts developing and commercializing UC Irvine-based discoveries and patents, he was awarded the Entrepreneurial Leader of the Year award in 2021.
Robert Spitale is the co-Founder and CEO of NovoGlia, Inc., a biotechnology company focused on developing microglia cell therapies to treat neurological diseases. Before founding NovoGlia, he was Professor and Founding Associate Dean of Research at the University of California, Irvine (UCI) in the School of Pharmacy & Pharmaceutical Sciences. At UCI, his lab is focused on developing novel chemical methods to understand the role of RNA molecules in normal cell biology and disease. In addition, he co-developed methods to derive human microglia cells from induced pluripotent stem cells to study their role in disease and as potential therapeutics – this work led to the founding of NovoGlia. For his work at UCI, he was recognized with an NIH NewInnovator Award, Pew Biomedical Scholar, Keck Biomedical Grantee, Ono PharmaceuticalsBreakthrough Science Initiative Award, the International Chemical Biology Society YoungChemical Biologist Award, and a Chan-Zuckerberg Collaborative Pairs in NeurodegenerativeResearch Award.
Built companies with unique clinical data assets and machine learning/clinical algorithms into market leaders. Results-oriented executive leading energetic, client-centric company transformations. Current LP in funds that invest in small molecules+diagnostics using AI.
David Ferrera is an engineer, entrepreneur, inventor and advisor with nearly 30 years of experience in the medical device field successfully developing products, founding companies, and managing them from concept through commercialization. He’s author of Innovation in Translation - How Big Ideas Really Happen Published by Advantage-Forbes in 2021. He’s currently CEO of RC Medical, a medical device venture studio that is funding, designing, developing and commercializing products for the interventional radiology markets. RC Medical works with physician-entrepreneurs to identify new product technology and indications of medical devices. RC Medical has formed several newcos recently with physicians to create product-based solutions for problems they encounter every day in the interventional suite. The first newcos founded from RC Medical are Single Pass, Infinity Neuro and Sonorous NV.
NexCore Group is a national healthcare real estate investment and development company that focuses on acquiring, developing, owning and managing healthcare facilities including medical office buildings, wellness facilities, ambulatory surgery centers, single and multi-specialty physician buildings, life sciences facilities, seniors housing communities and transitional rehabilitation centers. NexCore has completed $4.7 billion in healthcare real estate transactions throughout 29 states, developed and acquired over 14.3 million square feet of healthcare properties across the country and currently manages over $2.9 billion of healthcare facilities spanning 7.3 million square feet. The company has been recognized repeatedly as one of the Top Healthcare Real Estate Developers in the U.S. by Modern Healthcare and HREI.
HATCHspaces ®, LLC is a Los Angeles-based real estate development platform focused on simplifying the process of scientific innovation by creating purpose-built life sciences facilities for companies emerging from academic and incubator networks. With properties in various regional submarkets, HATCHspaces’® mission is to deliver the life science community state-of-the-art lab facilities at varying scales, allowing regions to retain early-stage bioscience and biotechnology start-ups emerging from research environments.
-1.jpg?width=300&height=77&name=InsperityLogo_HR-Difference-Tag_CMYK%20(1)-1.jpg)
Our tagline, HR that Makes a Difference™, defines what we do. It emphasizes that human resources is a key driver of growth and contributes to a business’s bottom line. This is what sets Insperity apart.
Insperity has a long history of improving the success equation of small and midsize businesses across the country – because when businesses succeed, communities prosper.
And in today’s changing business environment, it’s our privilege to take care of an organization’s most valuable asset: its people.
For over 28 years, Biocom California has helped move the life science industry forward with transformative resources that enable companies to make meaningful connections. Biocom California harnesses the collective power and experience of the most innovative and productive life science clusters in the world, with powerful advocacy and transformative programs to help companies in their quest to improve the human condition.
Do you have a great company in the bioscience or medtech industry? Do you need wet-lab and/or fabrication space to develop and test your product?
